Trial · NCT07584278
Probiotics and Biomarkers in Irritable Bowel Syndrome
The goal of this double-blind parallel-arm randomized controlled trial is to learn if a probiotic supplement (containing a new strain derived from L. reuteri) a
- Status
- Recruiting
- Sponsor
- Sahlgrenska University Hospital
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 252 participants (planned)
- Start
- Apr 28, 2026
- Primary completion
- April 2031
- Conditions
- Irritable Bowel Syndrome (IBS)
Summary
The goal of this double-blind parallel-arm randomized controlled trial is to learn if a probiotic supplement (containing a new strain derived from L. reuteri) alters outcomes related to symptom severity and transit time in adults with irritable bowel syndrome (IBS). The main question it aims to answer is: Does the probiotic alter IBS symptom severity? Researchers will compare the probiotic to a placebo (a lookalike substance that contains no probiotic) to see if the probiotic works to alter outcomes.
Interventions
- Probiotic Supplementation (Lactobacillus Reuteri) Other
- Placebo Supplementation Other
Locations
1 country: Sweden.
| Facility | City | Country |
|---|---|---|
| Mag-tarmlab, Sahlgrenska University Hospital | Gothenburg | Sweden |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.